431. Deputy Richard Boyd Barrett asked the Minister for Health if, in view of the National Centre for Pharmacoeconomics report that the drug Orkambi prolongs life by a median 7.4 years, 2.45 QALY and the cost-effectiveness threshold of €30,000 per annum, if he will advise of the average cost and lowest cost per annum charged for the drug in the EU; if the HSE will make an offer to the manufacturer in view of these facts; and if he will make a statement on the matter. [35958/16]

Summary

431. Deputy Richard Boyd Barrett asked the Minister for Health if, in view of the National Centre for Pharmacoeconomics report that the drug Orkambi prolongs life by a median 7.4 years, 2.45 QALY and the cost-effectiveness threshold of €30,000 per annum, if he will advise of the average cost and lowest cost per annum charged for the drug in the EU; if the HSE will make an offer to the manufacturer in view of these facts; and if he will make a statement on the matter. [35958/16]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Data

  xml · EN · 22 November 2016

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.